Skip to content
ppharmaranks
Menu

Hims & Hers review: what it prescribes, what it costs, who it suits

FDA-approved (after a 2026 pivot). A publicly-traded platform that has moved decisively to FDA-approved medicine and is one of the few offering the oral Wegovy pill cheaply. The trade-off is the thinnest clinical touch here: async-only, no labs — fine for a straightforward start, less so if your history is complicated.

By the pharmaranks editorial teamReviewed against the FDA (approval status, shortage record, 2026 enforcement) and each service's own current published terms sourcesUpdated Aug 2, 2026How we research
What it prescribes
Now centered on branded, FDA-approved semaglutide — injectable Wegovy (including the higher-dose 7.2 mg), the oral Wegovy pill, and Ozempic. Hims received one of the FDA's 2025 warning letters over compounded-GLP-1 marketing, then settled with Novo Nordisk in March 2026 and moved new patients to branded products, saying it will no longer advertise compounded GLP-1s and will keep them only for the limited set of patients whose clinical needs a commercial product cannot meet.
How the consult works
Asynchronous only — a provider reviews your intake and replies by message, usually within a day. No video visits, and no lab work is ordered or required.
Insurance
Now bills commercial insurance for the branded drugs (new since the branded pivot) and integrates the Novo Nordisk savings card; a covered patient can reach a very low copay.
What it costs
A weight-loss membership (about $39 the first month, then roughly $149/mo) with the drug separate — oral Wegovy from about $149/mo and injectable Wegovy around $299/mo self-pay. As of mid-2026 — verify current.

What to watch with Hims & Hers

Async-only means no clinician actually sees or examines you — you are responsible for flagging your full history in the intake.

Go to Hims & Hers

Visit Hims & Hers

We earn nothing from this link. We have no commercial relationship with Hims & Hers, and the link is here because the page would be less useful without it.

Frequently asked questions

Does Hims & Hers prescribe FDA-approved GLP-1s or compounded copies?

FDA-approved (after a 2026 pivot). Now centered on branded, FDA-approved semaglutide — injectable Wegovy (including the higher-dose 7.2 mg), the oral Wegovy pill, and Ozempic. Hims received one of the FDA's 2025 warning letters over compounded-GLP-1 marketing, then settled with Novo Nordisk in March 2026 and moved new patients to branded products, saying it will no longer advertise compounded GLP-1s and will keep them only for the limited set of patients whose clinical needs a commercial product cannot meet.

How does a Hims & Hers consultation work?

Asynchronous only — a provider reviews your intake and replies by message, usually within a day. No video visits, and no lab work is ordered or required.

Does Hims & Hers take insurance?

Now bills commercial insurance for the branded drugs (new since the branded pivot) and integrates the Novo Nordisk savings card; a covered patient can reach a very low copay.

What does Hims & Hers cost?

A weight-loss membership (about $39 the first month, then roughly $149/mo) with the drug separate — oral Wegovy from about $149/mo and injectable Wegovy around $299/mo self-pay. As of mid-2026 — verify current. Prices in this market move quickly — treat this as the shape of the bill, not a quote.

Is a compounded GLP-1 from any service the same as the branded drug?

No. A compounded product is not FDA-approved: the agency has not reviewed that specific product for identity, potency, purity or sterility. The shortages that made routine compounding lawful ended — tirzepatide October 2, 2024, semaglutide February 21, 2025 — and in 2026 the FDA has been issuing warning letters to telehealth companies over how compounded GLP-1s are marketed. That is the single fact that reorders this market, and it applies whichever service you pick.

Compare with the others

All seven compared side by side →

Sources: Hims — Weight Loss · Hims & Hers — Strategic shift to FDA-approved GLP-1s / Novo Nordisk collaboration (Mar 9, 2026) · FDA — Warning letter, Hims & Hers Health, Inc. dba Hers (Sep 9, 2025)

We rate medicines, not companies, and we do not give a telehealth service a score — our ratings are built on FDA recall data about drugs, and no equivalent data exists about a business. Prices and programme terms in this market change quickly; verify the current terms on the service’s own site before paying. Not medical advice.